metronidazole has been researched along with Arterial Occlusive Diseases in 4 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of topical metronidazole has been limited to the treatment of acne rosacea, infected foot ulcers associated with diabetes mellitus, varicose veins, postirradiation ulcers, and dental conditions since the Food and Drug Administration approved the drug in 1988." | 3.69 | Topical metronidazole for arterial insufficiency ulcers. ( Gibson, LB; Kaplan, B, 1995) |
| " In this study the pharmacokinetic profiles of different dosing regimens utilizing these drugs during reconstructive vascular procedures are presented." | 2.67 | Optimizing antimicrobial prophylaxis in reconstructive vascular surgery. ( Agema, A; Degener, JE; Dijkstra, PK; Sikkema, B; van der Goot, L; van der Meer, AL; Voesten, HG, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vutskits, Z | 1 |
| Kaplan, B | 1 |
| Gibson, LB | 1 |
| Voesten, HG | 1 |
| Degener, JE | 1 |
| Dijkstra, PK | 1 |
| van der Goot, L | 1 |
| Agema, A | 1 |
| Sikkema, B | 1 |
| van der Meer, AL | 1 |
| Jones, TH | 1 |
| Bergvall, V | 1 |
| Bradshaw, JP | 1 |
1 trial available for metronidazole and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Optimizing antimicrobial prophylaxis in reconstructive vascular surgery.
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Aorta, Abdominal; Arterial Occlusi | 1993 |
3 other studies available for metronidazole and Arterial Occlusive Diseases
| Article | Year |
|---|---|
[The role of metronidazole (Klion) in the prevention of anaerobic wound infection in vascular diseases].
Topics: Amputation Stumps; Arterial Occlusive Diseases; Gas Gangrene; Humans; Leg; Metronidazole; Surgical W | 1982 |
Topical metronidazole for arterial insufficiency ulcers.
Topics: Administration, Topical; Adult; Arterial Occlusive Diseases; Cellulitis; Foot Ulcer; Humans; Leg; Ma | 1995 |
Carotid artery stenoses and thrombosis secondary to cavernous sinus thromboses in Fusobacterium necrophorum meningitis.
Topics: Adult; Arterial Occlusive Diseases; Carotid Artery Diseases; Carotid Artery Thrombosis; Cavernous Si | 1990 |